Foresite Capital Management Vi LLC / TCE2
Foresite Capital Management Vi LLC’s Celldex Therapeutics Inc New Position
Does Foresite Capital Management Vi LLC own Celldex Therapeutics Inc New (TCE2)? Yes — 315.9K shares worth $10M (+2.18% of its 13F portfolio) as of Q1 2026.
Position Value
$10M
Q1 2026
Shares
315.9K
% of Portfolio
+2.18%
Quarters Held
1
currently held
Position History TCE2
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 315.9K | $10M | +2.18% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Foresite Capital Management Vi LLC’s full portfolio or all institutional holders of TCE2.